Mylan Laboratories, Inc. v. Matkari

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

• holding that the plaintiff’s “claims that the defendants falsely represented that their drugs had been ‘properly approved by the FDA’ must fail”
• “In considering a motion to dismiss, the court favorable to the plaintiff.”
• “Congress did not draft the federal limitations period to 8 begin running only at the end of a particular state’s exhaustion process. Instead, the 9 statute is clear that the limitations period starts from the latest of four specific dates.”
• claim that the act of placing a drug on the market with package inserts often used for FDA-approved drugs falsely implies that the drug has received FDA approval, in the absence of a specific statement reflecting ‘FDA approval,’ is ‘too great a stretch under the Lanham Act’

Source: CourtListener parenthetical corpus (CC0).